• Client List
 • Request Client Information
 • Client Press Releases
 • Client Events
 • Testimonials

5/16/2013	MAXIMUS Launches Independent Medical and Bill Review Services for California Workers’ Compensation Programs
5/16/2013	Bio-Path Holdings Reports First Quarter 2013 Operational and Financial Results
5/15/2013	SIGMA-TAU RECEIVES INNOVATION AWARD FROM THE NATIONAL ORGANIZATION FOR RARE DISORDERS FOR ITS ADVANCEMENTS IN RARE DISEASES
5/15/2013	MAXIMUS to Operate the Vermont Health Connect Customer Support Center
5/13/2013	PDI Reports 2013 First Quarter Financial Results
5/9/2013	MAXIMUS Reports Financial Results for Second Quarter of Fiscal 2013 Company Reiterates Guidance
5/8/2013	Retrophin Names Marc L. Panoff as Chief Financial Officer
5/3/2013	CIPHER REPORTS RECORD FINANCIAL RESULTS FOR Q1 2013
5/1/2013	SIGMA-TAU PHARMACEUTICALS LAUNCHES CYSTARAN™ FOR THE TREATMENT OF CORNEAL CYSTINE CRYSTAL ACCUMULATION IN PATIENTS WITH CYSTINOSIS
5/1/2013	PDI, Inc. to Hold First Quarter 2013 Financial Results Conference Call on Tuesday, May 14, 2013
4/29/2013	DAVE LEMUS PROMOTED TO CHIEF EXECUTIVE OFFICER OF SIGMA-TAU PHARMACEUTICALS, INC.
4/25/2013	Highlights for the first quarter 2013
4/25/2013	Alexion Broadens and Strengthens its Executive Leadership Team
4/25/2013	Retrophin Names Horacio Plotkin, M.D. as Chief Medical Officer
4/25/2013	Alexion Reports First Quarter 2013 Results
4/24/2013	MAXIMUS Schedules Fiscal 2013 Second Quarter Conference Call
4/18/2013	MAXIMUS Announces Two-for-One Stock Split and Quarterly Cash Dividend
4/17/2013	NEW DATA SHOW PHARMATHENE’S RECOMBINANT BIOSCAVENGER BINDS TO A BROAD SPECTRUM OF CHEMICAL NERVE AGENTS
4/11/2013	Alexion Pharmaceuticals to Report First Quarter 2013 Results on Thursday, April 25, 2013
4/10/2013	PHOTOCURE ANNOUNCES POSITIVE FINAL RESULTS OF PHASE 2B CEVIRA® STUDY
4/8/2013	Retrophin Sponsors Seventh International NBIA Disorders Association Family Conference
4/3/2013	Updated European Association of Urology Guidelines Strengthen Recommendation on Use of Hexvix®
4/3/2013	TetraLogic Pharmaceuticals Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2013
4/2/2013	Bio-Path Holdings Reports Fiscal Year 2012 Operational and Financial Results
4/2/2013	Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-end 2012 Financial Results
3/27/2013	Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring Committee for Pivotal Phase lll Clinical Trial for Firdapse™
3/13/2013	PDI, Inc. Announces $17 Million Multi-Year Sales Contract
3/7/2013	ADMA Biologics Commences Pivotal Phase III Clinical Study of RI-002 in PIDD Patients
3/7/2013	Bio-Path Holdings Begins Enrollment in Fifth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias
3/6/2013	ADMA Biologics Reports 2012 Year End Financial and Operational Results
3/6/2013	PDI Reports 2012 Fourth Quarter and Year End Financial Results
3/5/2013	Catalyst Pharmaceutical Partners Appoints Dr. Bernardino Mosquera as Vice President of Clinical Operations
3/1/2013	CIPHER REPORTS RECORD FINANCIAL RESULTS FOR 2012
2/28/2013	Alexion Joins Eurordis, NORD and Patient Organizations Worldwide in Celebrating Rare Disease Day 2013
2/28/2013	PDI, Inc. to Hold Fourth Quarter and Full Year 2012 Financial Results Conference Call on Thursday, March 7, 2013
2/21/2013	Catalyst Pharmaceutical Partners Launches New Website
2/14/2013	Alexion Reports Fourth Quarter and Full Year 2012 Results
2/12/2013	Retrophin Raises $10.0 Million in Private Placement
2/11/2013	Catalyst Pharmaceutical Partners Provides Update on Research and Development Pipeline
2/7/2013	Alexion Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation
1/28/2013	TetraLogic Pharmaceuticals Announces Decision to Grant Japanese Patent on Birinapant
12/10/2012	TetraLogic Pharmaceuticals Announces Presentation on Smac Mimetic Birinapant at American Society of Hematology (ASH) Annual Meeting
12/10/2012	New Data Highlighting Long-Term Efficacy and Safety Outcomes of PNH Patients Treated with Soliris® Reported at ASH Annual Meeting
12/6/2012	PHOTOCURE ANNOUNCES POSITIVE RESULTS OF CEVIRA® STUDY RESULTS DEMONSTRATE SIGNIFICANT EFFICACY IN TREATMENT OF LESIONS AND ONCOGENIC HUMAN PAPILLOMA VIRUS IN PATIENTS WITH PRECANCEROUS LESIONS OF THE CERVIX
12/6/2012	Bio-Path Holdings to Expand Development of Liposomal Grb-2 into two Additional Indications: Triple Negative and Inflammatory Breast Cancers
12/6/2012	TetraLogic Pharmaceuticals’ Smac Mimetic Birinapant Selected for Oral Presentation at the 17th Japanese Foundation for Cancer Research – International Symposium on Cancer Chemotherapy
11/16/2012	Bio-Path Holdings Reports Third Quarter 2012 Operational and Financial Results
11/14/2012	Bio-Path Holdings Successfully Completes Fourth Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
11/8/2012	Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II(b) Trial for Cocaine Addiction
11/7/2012	Researchers to Present Additional Data on Soliris® (eculizumab) as a Treatment for Patients with PNH and aHUS at ASH Annual Meeting
11/5/2012	Omthera Pharmaceuticals Presents Successful Phase 3 Results from EVOLVE and ESPRIT Clinical Studies for Epanova™; Both Trials Meet Primary and Secondary Endpoints
11/3/2012	Two-Year Data Show Long-Term Benefits of Chronic Soliris® Therapy in Patients with aHUS
11/3/2012	New Clinical Trial Data Show Substantial Improvement with Eculizumab (Soliris®) in Patients with STEC-HUS
10/22/2012	PDI, Inc. Promotes Gerald R. Melillo, Jr. to President, Sales Services
10/10/2012	Researchers to Present Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS and STEC-HUS at ASN Annual Meeting
10/9/2012	TetraLogic Pharmaceuticals Granted Third U.S. Patent on Birinapant
10/9/2012	Data from Investigator-Initiated Phase 2 Study of Eculizumab (Soliris®) in Patients with Severe Relapsing Neuromyelitis Optica (NMO) Presented at the American Neurological Association (ANA) Annual Meeting
10/4/2012	Bio-Path Holdings Adds New Board Member
8/16/2012	Bio-Path Holdings Reports Second Quarter 2012 Operational and Financial Results
7/25/2012	Bio-Path Holdings Begins Enrollment in Fourth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias
7/24/2012	PDI, Inc. Announces $29 Million in New and Extended Sales Contracts
7/24/2012	ADMA Biologics Appoints Plasma Industry Leader Lawrence Guiheen to Board of Directors
7/23/2012	ADMA Biologics Appoints James Mond, M.D., Ph.D. as Chief Medical and Scientific Officer
7/18/2012	PDI, Inc. Announces Client FDA Product Approval Related to Previously Disclosed Contract
6/17/2012	New Data Show Majority of Patients with aHUS Experienced Systemic Multi-Organ Complications Prior to Treatment
6/4/2012	Data from Phase 1 and Phase 1B Studies of NewLink Genetics’ IDO Pathway Inhibitor (NLG8189) Presented at 2012 ASCO Annual Meeting
6/4/2012	NewLink Genetics reports Two- and Three-year Overall Survival data from its Phase-2 HyperAcute® Pancreas (algenpantucel-L) Immunotherapy trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
6/4/2012	Bio-Path Holdings Shares Commence Trading On OTCQX, The Top Tier Of The OTC Market
6/4/2012	NewLink Genetics HyperAcute® Lung (tergenpumatucel-L) Immunotherapy Demonstrates a Correlation Between Immune Response and Survival in Patients with Non-Small Cell Lung Cancer
6/1/2012	Data from an Investigator-Initiated Phase 2 Study of NewLink Genetics' HyperAcute® Melanoma Immunotherapy Published in 2012 ASCO Annual Meeting Abstracts
5/29/2012	Bio-Path Holdings Successfully Completes Third Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
5/24/2012	PDI, Inc. Announces New Business Win Valued At $57 Million
5/17/2012	Bio-Path Holdings Reports First Quarter 2012 Operational and Financial Results
5/14/2012	PDI, Inc. Announces $16 Million in New, Renewal Sales Contracts
5/11/2012	New Clinical Trial Data Show Substantial Improvement with Eculizumab (Soliris®) in Patients with STEC-HUS
4/26/2012	Complix’ Alphabody™ Protein Therapeutics Demonstrate Activity against both Undruggable Extracellular and Intracellular Disease Targets
4/3/2012	Bio-Path Holdings Reports Fiscal Year 2011 Operational and Financial Results
3/29/2012	Asfotase Alfa Significantly Decreased TNSALP Substrates and Improved 6-Minute Walk Test Results in Adolescents and Adults with Hypophosphatasia (HPP)
3/7/2012	New England Journal of Medicine Publishes Data from Phase 2 Study of Asfotase Alfa in Life-Threatening Hypophosphatasia
2/7/2012	Alexion Completes Acquisition of Enobia Pharma Corp.
2/7/2012	Bio-Path Holdings Successfully Completes Second Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
2/2/2012	ThromboGenics Announces that the FDA Intends to Grant Ocriplasmin Priority Review
12/28/2011	Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP)
12/23/2011	ThromboGenics Submits Biologics License Application for Ocriplasmin to the U.S. FDA
12/16/2011	ThromboGenics and BioInvent Complete Enrollment of Phase IIb Trial with TB-402 ahead of schedule
12/13/2011	Bio-Path Holdings’ Initial Phase I Data in Leukemia Clinical Trial Demonstrates that Its Neutral Lipid Delivery Technology Antisense Drug BP-100-1.01 (Liposomal Grb-2) Is Well Tolerated with Activity Seen at Low-Starting Dose
11/29/2011	Soliris® (eculizumab) Granted Marketing Authorization in Europe for Treatment of Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
11/29/2011	Soliris® (eculizumab) Granted Marketing Authorization in Europe for Treatment of Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
11/24/2011	ThromboGenics Appoints Thomas Clay as New Board Member
11/15/2011	Bio-Path Holdings Reports Third Quarter 2011 Financial Results
10/20/2011	ThromboGenics Announces Dr Julia Haller to Present Ocriplasmin Phase III Responder Analysis at Opening Session of AAO (American Academy of Ophthalmology) Retina Subspecialty Day
10/19/2011	ThromboGenics Announces EMA Acceptance for Review of Marketing Authorisation Application for Ocriplasmin
10/4/2011	Initial Data from Bio-Path Holding’s Phase I Clinical Trial Accepted for Presentation at American Society of Hematology Annual Meeting
9/23/2011	Soliris® (eculizumab) Approved by FDA for All Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
9/23/2011	Alexion Receives CHMP Positive Opinion for Soliris® (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) in the European Union
9/14/2011	Phase 2 Study of Eculizumab (Soliris®) in Patients with Severe and Refractory Generalized Myasthenia Gravis Presented at MGFA Annual Meeting
8/22/2011	ThromboGenics Announces New Phase III Ocriplasmin Data Presented at the 2011 Annual Meeting of the American Society of Retina Specialists (ASRS)
8/15/2011	Bio-Path Holdings Reports Second Quarter 2011 Financial Results
8/11/2011	First Cohort Successfully Completed in Bio-Path Holding’s Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
8/9/2011	ThromboGenics on Track to File Ocriplasmin by End of 2011
7/19/2011	Bio-Path Holdings Announces the Relocation of Corporate Headquarters to Houston, Texas
6/20/2011	Alexion Initiates Clinical Trial of Eculizumab as a Potential Treatment for Patients with STEC-HUS in Expanded Response to EHEC Crisis in Germany
6/14/2011	METHYLGENE REPORTS FIRST QUARTER 2011 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
6/11/2011	New Data Show Renal Impairment Is Strong Predictor of Early Death in Patients with PNH
6/11/2011	Researchers Present Final Data from Phase 2 Studies of Soliris® (eculizumab) in Patients with aHUS
6/3/2011	METHYLGENE REPORTS CLINICAL DATA FOR MGCD265 AT THE 2011 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
6/1/2011	FDA Grants Priority Review for Alexion’s sBLA for Soliris®(eculizumab) as a Treatment for Patients with atypical Hemolytic Uremic Syndrome (aHUS)
5/23/2011	Researchers to Present Nine Studies on Soliris® (eculizumab) in Patients with PNH and aHUS at EHA Congress
5/19/2011	METHYLGENE TO PRESENT MGCD265 DATA AT THE 2011 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
5/17/2011	Bio-Path Holdings Reports First Quarter 2011 Financial Results
5/16/2011	ThromboGenics and BioInvent Announce the Start of New Study of Novel Antibody Anti-Cancer Agent TB-403 (Anti-PlGF) by Partner Roche
5/12/2011	Alexion Shareholders Approve Increase in Authorized Shares For Previously Announced Stock Split
4/28/2011	Bio-Path Holdings Appoints Dr. Ana M. Tari Director, Preclinical Operations and Research
4/27/2011	ThromboGenics and BioInvent Have Dosed the First Patient in Phase IIb Trial of TB-402 (Anti-Factor VIII) for Venous Thromboembolism (VTE) Prophylaxis
4/7/2011	Alexion Submits Applications for Soliris® (eculizumab) as a Treatment for Patients with atypical Hemolytic Uremic Syndrome (aHUS) in the United States and European Union
4/5/2011	METHYLGENE PRESENTS PRECLINICAL DATA FOR MGCD265 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING
4/1/2011	Thrombogenics increases share capital through warrant exercises
3/31/2011	Bio-Path Holdings Reports Fiscal Year 2010 Operational and Financial Results
3/30/2011	Alexion Announces Two-For-One Stock Split
3/30/2011	METHYLGENE REPORTS FOURTH QUARTER AND FULL YEAR 2010 FINANCIAL RESULTS
3/14/2011	Nile Therapeutics Reports 2010 Fourth Quarter and Full Year Financial Results
3/11/2011	ThromboGenics NV – Business Update
3/10/2011	ThromboGenics Announces Business Update and 2010 Full-Year Results
2/28/2011	Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure
2/28/2011	Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease
2/28/2011	Alexion Joins NORD, EURORDIS and Other Patient Advocacy Groups in Supporting the Goals of Rare Disease Day 2011
2/11/2011	Positive TB-402 (Anti-Factor VIII Antibody) Phase II Data Published in Journal of Thrombosis and Haemostasis
2/10/2011	Alexion Reports Fourth Quarter and Full Year 2010 Results
2/10/2011	Alexion Acquires Investigational Therapy for Infants Suffering From Catastrophic, Ultra-Rare Genetic Neurologic Disorder
1/31/2011	Alexion Acquires Taligen Therapeutics and Creates Translational Medicine Group to Accelerate Development of Expanded Portfolio
1/21/2011	CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
1/18/2011	CureFAKtor Pharmaceuticals Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer
1/7/2011	Omthera Pharmaceuticals Reports Favorable Pharmacokinetics Data from ECLIPSE Trial
12/6/2010	Long-Term Efficacy, Safety and Survival Outcomes of PNH Patients Treated with Soliris® (eculizumab) Reported at ASH Annual Meeting
12/6/2010	Hemolysis Is Associated with Increased Mortality and Thrombosis in Patients with PNH
12/5/2010	Alexion Reports Results from First Clinical Trial of Novel Anti-Cancer Antibody Samalizumab at ASH Annual Meeting
11/29/2010	METHYLGENE TO PRESENT CLINICAL DATA AT THE 52nd AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING
11/24/2010	Glycotex, Inc. Awarded Cash Grant Under the U.S. Government Qualifying Therapeutic Discovery Program
11/20/2010	Phase 2 Study of Eculizumab (Soliris®) in Patients with aHUS Resistant to Plasma Therapy Met Primary and Secondary Endpoints with High Statistical and Clinical Significance
11/18/2010	METHYLGENE PRESENTS ENCOURAGING CLINICAL DATA FOR MGCD265 IN SOLID TUMOR CANCERS AT THE 22nd EORTC-NCI-AACR ANNUAL MEETING
11/15/2010	Bio-Path Holdings Reports Third Quarter 2010 Financial Results
11/12/2010	METHYLGENE REPORTS THIRD QUARTER 2010 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE FOR MGCD265
11/10/2010	METHYLGENE TO PRESENT AT THE 22ND EORTC-NCI-AACR SYMPOSIUM
11/8/2010	Researchers to Present New Long-Term Data on Soliris® (eculizumab) in Patients with PNH at the ASH Annual Meeting
11/5/2010	ThromboGenics NV – Business Update
11/3/2010	Bio-Path Holdings Awarded Grant From The U.S. Government’s Qualifying Therapeutic Discovery Project Program
11/2/2010	Nile Therapeutics Phase 2 Study of CD-NP in Patients with Acute Decompensated Heart Failure meets Primary Endpoint, Has Favorable Trends on Renal Function
10/20/2010	METHYLGENE’S LEAD PROGRAM, MGCD265, NOMINATED “TOP TEN ONCOLOGY PROJECTS TO WATCH” BY WINDHOVER AND CAMPBELL ALLIANCE
9/30/2010	ThromboGenics Signs Deal with MSD for Long-Term Commercial Supply of Microplasmin
9/28/2010	METHYLGENE ISSUED KEY PATENTS FOR LEAD ONCOLOGY PROGRAM
9/16/2010	METHYLGENE ENTERS INTO $15 MILLION EQUITY LINE FACILITY AGREEMENT
9/13/2010	METHYLGENE ANNOUNCES CHANGES TO SENIOR MANAGEMENT
9/13/2010	METHYLGENE PRESENTS PHASE I DATA FOR ITS NOVEL ANTIFUNGAL AGENT, MGCD290, AT THE 50TH ANNUAL ICAAC MEETING
9/6/2010	ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin’s Potential to Transform the Treatment of Retinal Disorders
9/1/2010	Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
8/26/2010	ThromboGenics NV Announces 2010 First Half Results
8/23/2010	ALEXION RECEIVES FDA APPROVAL OF RHODE ISLAND MANUFACTURING FACILITY FOR SOLIRIS® SUPPLY
7/30/2010	METHYLGENE REPORTS SECOND QUARTER 2010 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE FOR MGCD265
7/22/2010	ALEXION REPORTS SECOND QUARTER 2010 RESULTS
7/15/2010	ThromboGenics Announces Publication of Positive Microplasmin Phase II Data in the Journal Retina
7/9/2010	Positive Results from Phase II VTE Prophylaxis Study with TB-402 (Anti-Factor VIII) Presented at the 21st International Congress on Thrombosis in Milan, Italy
7/1/2010	ThromboGenics to Present Results of Second Phase III Trial of Microplasmin at the 28th Annual Meeting of the American Society of Retina Specialists (ASRS) and the 10th EURETINA Congress
6/30/2010	METHYLGENE FURTHER EXTENDS COLLABORATION WITH OTSUKA PHARMACEUTICAL FOR THE DEVELOPMENT OF KINASE INHIBITORS FOR TREATMENT OF OCULAR DISEASES
6/15/2010	Early Clinical Experience and Basic Science Support Further Investigation of Soliris® (eculizumab) for the Treatment of Patients with Thrombotic Microangiopathy
6/14/2010	Substantial Disease Burden of PNH Demonstrated in Data from International and Asian Patient Registries Presented at European Hematology Association
6/7/2010	METHYLGENE PRESENTS CLINICAL DATA FOR MOCETINOSTAT AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2010 ANNUAL MEETING
6/7/2010	METHYLGENE PRESENTS ENCOURAGING CLINICAL AND PRECLINICAL DATA FOR MGCD265 AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2010 ANNUAL MEETING
6/7/2010	ThromboGenics Presents New Exciting Microplasmin Phase III Data at the World Ophthalmology Congress (WOC) in Berlin
6/1/2010	Alexion Announces the Appointment of Ann M. Veneman to Its Board of Directors
5/21/2010	DATA FROM METHYLGENE’S MGCD265 AND MOCETINOSTAT CLINICAL TRIALS TO BE PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
5/19/2010	METHYLGENE ANNOUNCES COMPLETION OF NON-DILUTIVE FINANCING
5/17/2010	ThromboGenics and BioInvent to Receive €10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
5/14/2010	METHYLGENE SHAREHOLDERS APPROVE NON-DILUTIVE FINANCING OF UP TO $9.1 MILLION AND COMPANY REPORTS FIRST QUARTER 2010 FINANCIAL RESULTS
5/11/2010	ThromboGenics NV – Business Update
5/6/2010	ThromboGenics and BioInvent Announce Positive Topline Results from Phase II VTE Prophylaxis Study with Anti-Factor VIII (TB-402)
4/30/2010	Research to be Presented at the American Transplant Congress Examines the Role of Terminal Complement Inhibition in the Treatment of Kidney Transplantation Patients
4/23/2010	METHYLGENE ANNOUNCES ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS AND PROVIDES CORPORATE UPDATE
4/20/2010	METHYLGENE PRESENTS PRECLINICAL DATA FOR MGCD265 (A MULTI-TARGETED MET KINASE INHIBITOR) AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING
4/20/2010	ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for the Non-Surgical Treatment of Symptomatic Vitreomacular Adhesion (VMA)
4/16/2010	METHYLGENE TO PRESENT MGCD265 DATA AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING
4/16/2010	Alexion’s Soliris® (Eculizumab) Receives Marketing Approval in Japan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
2/24/2010	EMISPHERE TECHNOLOGIES ANNOUNCES EXTENSION OF MATURITY DATE FOR CONVERTIBLE PROMISSORY NOTE
2/9/2010	ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
2/8/2010	NEXMED RECEIVES OVER $2.7 MILLION CASH INFUSION
2/1/2010	NEXMED GRANTED REQUEST FOR CONTINUED LISTING ON NASDAQ
12/16/2009	ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
12/11/2009	ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-related Macular Degeneration (AMD)
12/7/2009	Soliris® Reduced Hemolysis, Lowered Thrombosis Rate and Improved Quality of Life in Patients with PNHWho Had Previously Never Been Transfused
12/7/2009	Soliris® Reversed Thrombocytopenia in Patients with Both PNH and Pre-Existing Thrombocytopenia in Study Presented at ASH Annual Meeting
12/6/2009	Soliris® Reduced Hemolysis, Decreased Transfusion Requirements and Improved Fatigue in Patients with PNH and Bone Marrow Insufficiency Disorders
12/6/2009	Researchers Report Clinical Association Between Type II PNH Cells and Thrombocytopenia
12/4/2009	Long-Term Soliris® Treatment Resulted in Sustained Reduction in Hemolysis and Improved Kidney Function in Japanese Patients with PNH
11/17/2009	METHYLGENE REPORTS FAVORABLE PHASE I DATA FOR MGCD265 IN SOLID TUMORS AT THE AACR-NCI-EORTC INTERNATIONAL CONFERENCE
11/17/2009	ThromboGenics and BioInvent Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients with Advanced Solid Tumours
11/5/2009	METHYLGENE REPORTS THIRD QUARTER 2009 FINANCIAL RESULTS
11/4/2009	ThromboGenics NV Business Update
10/20/2009	STUDY RESULTS: NOVEL ORAL PTH FORMULATION USING EMISPHERE’S ELIGEN® TECHNOLOGY SHOWED POTENTIAL THERAPEUTICAL ADVANTAGES TO AVAILABLE INJECTABLE PTH IN POSTMENOPAUSAL OSTEOPOROTIC WOMEN
10/15/2009	STUDY RESULTS SUGGEST ORAL SALMON CALCITONIN USING ELIGEN® DRUG DELIVERY TECHNOLOGY MAY REDUCE CARTILAGE AND BONE DEGRADATION IN OSTEOARTHRITIS
10/14/2009	METHYLGENE ANNOUNCES EQUITY INVESTMENT FROM OTSUKA PHARMACEUTICAL CO., LTD.
10/13/2009	Transdel Pharmaceuticals Appoints Dr. Joachim P.H. Schupp as Chief Medical Officer
10/8/2009	EMISPHERE TECHNOLOGIES INTRODUCES FIRST COMMERCIALLY AVAILABLE PRODUCT, ORAL ELIGEN® B12
10/6/2009	Transdel Pharmaceuticals Announces Positive Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel®
9/22/2009	Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
9/21/2009	METHYLGENE TO RESUME DEVELOPMENT OF ITS HDAC INHIBITOR, MGCD0103 (MOCETINOSTAT)
9/21/2009	Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
9/15/2009	METHYLGENE PRESENTS PHASE I DATA FOR ITS NOVEL ANTIFUNGAL AGENT, MGCD290, AT THE 49TH ANNUAL ICAAC MEETING
9/14/2009	METHYLGENE PRESENTS PRECLINICAL DATA FOR ITS BETA-LACTAMASE INHIBITOR, MG96077, AT THE 49TH ANNUAL ICAAC MEETING
9/9/2009	METHYLGENE AND OTSUKA PHARMACEUTICAL CO. LTD. EXTEND FUNDED RESEARCH COLLABORATION
9/8/2009	Emisphere Technologies Announces Publication in Clinical Pharmacology and Therapeutics of Encouraging Data from an Independent Clinical Study of an Oral Eligen-GLP-1 Formulation on Glucose Homeostasis
9/8/2009	METHYLGENE TO PRESENT DATA AT THE 49TH ANNUAL ICAAC MEETING
9/2/2009	METHYLGENE INITIATES PHASE II PROGRAM FOR MGCD265 IN SOLID TUMORS AND NON-SMALL CELL LUNG CANCER PATIENTS
8/21/2009	EMISPHERE TECHNOLOGIES ANNOUNCES CLOSING OF $4 MILLION REGISTERED DIRECT OFFERING AND $4 MILLION PRIVATE PLACEMENT
8/21/2009	MediciNova and Avigen Enter Into Definitive Agreement for Business Combination
8/19/2009	Emisphere Technologies to Raise $4 Million in Registered Direct Offering and Additional $4 Million in Private Placement
8/14/2009	MediciNova Reports Second Quarter 2009 Results
8/11/2009	Emisphere Technologies Announces Financial and Operational Results for the Second Quarter and First Six Months of 2009
8/10/2009	EMISPHERE TECHNOLOGIES INTRODUCES FIRST COMMERCIALLY AVAILABLE PRODUCT, ORAL ELIGEN® B12
8/6/2009	EUROPEAN COMMISSION AND U.S. FDA GRANT ALEXION’S SOLIRIS® (ECULIZUMAB) ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)
7/31/2009	METHYLGENE REPORTS SECOND QUARTER 2009 FINANCIAL RESULTS
7/28/2009	EMISPHERE’S SNAC CARRIER ACHIEVES GRAS STATUS FOR USE WITH NUTRIENTS ADDED TO FOODS AND DIETARY SUPPLEMENTS
7/23/2009	ALEXION REPORTS SECOND QUARTER 2009 RESULTS
7/21/2009	MediciNova to Evaluate MN-221 for the Treatment of Chronic Obstructive Pulmonary Disease Exacerbations
7/13/2009	MediciNova Announces Proposed Final Protocol for its Phase II Placebo-controlled Clinical Trial Evaluating MN-221 in Patients with Severe, Acute Exacerbations of Asthma
6/25/2009	MediciNova and Avigen Confirm Understanding for Key Terms for a Business Combination
6/22/2009	Arlene Morris Joins MediciNova's Audit Committee
6/22/2009	EMISPHERE TECHNOLOGIES, INC. AND SYRACUSE UNIVERSITY ENTER RESEARCH AGREEMENT TO TEST ORAL DRUG DELIVERY SYSTEMS
6/19/2009	Alexion Extends Its Commitment to a Green Footprint Through Its Ambitious New Solar Energy System
6/10/2009	Alexion's Soliris® Receives 2009 Prix Galien France for Most Innovative Drug for Rare Disease
6/8/2009	EMISPHERE TECHNOLOGIES, INC. RECEIVES NASDAQ PANEL DECISION
6/1/2009	EMISPHERE TECHNOLOGIES ANNOUNCES THE COMPLETION OF ENROLLMENT IN SECOND PHASE III STUDY FOR ORAL OSTEOARTHRITIS TREATMENT UTILIZING PROPRIETARY ELIGEN® TECHNOLOGY
5/29/2009	New Study Results Verify That PNH Cells Are Found in Majority of Patients with Bone Marrow Failure Syndromes
5/28/2009	METHYLGENE REPORTS FAVORABLE PRELIMINARY PHASE I DATA FOR MGCD265, ITS MULTI-TARGETED (C-MET) KINASE INHIBITOR, AT ASCO ANNUAL MEETING
5/28/2009	MediciNova Announces Plan to Modify its Phase II Placebo-controlled Clinical Trial Evaluating MN-221 in Patients with Severe, Acute Exacerbations of Asthma
5/28/2009	RESEARCHERS TO REPORT ON THE INVESTIGATIONAL USE OF ALEXION’S SOLIRIS® (ECULIZUMAB) TO PREVENT ANTIBODY-MEDIATED REJECTION IN HIGH-RISK KIDNEY TRANSPLANT PATIENTS
5/26/2009	EMISPHERE TECHNOLOGIES REPORTS ENCOURAGING DATA FROM INDEPENDENT CLINICAL STUDY ASSESSING THE EFFECTS OF ORAL GLP-1 AND PYY3-36, COMBINED WITH ELIGEN® TECHNOLOGY ON APPETITE SUPRESSION
5/21/2009	EMISPHERE TECHNOLOGIES RECEIVES MILESTONE PAYMENT FROM MANNKIND CORPORATION
5/19/2009	EMISPHERE TECHNOLOGIES APPOINTS FRANKLIN M. BERGER TO ITS BOARD OF DIRECTORS
5/15/2009	MediciNova Reports First Quarter 2009 Results
5/8/2009	METHYLGENE REPORTS FIRST QUARTER 2009 FINANCIAL RESULTS
5/7/2009	EMISPHERE TECHNOLOGIES, INC. REPORTS FIRST QUARTER 2009 FINANCIAL RESULTS
4/24/2009	Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
4/23/2009	ALEXION REPORTS FIRST QUARTER 2009 RESULTS
4/22/2009	MediciNova Reports Final Data from Phase II MN-221 Emergency Department Clinical Trial (MN-221-CL-006); Hospitalization Rates Decrease 45 Percent with MN-221 Plus Standardized Care in Asthma Patients
4/22/2009	Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
4/22/2009	Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
4/21/2009	METHYLGENE PRESENTS PRECLINICAL DATA FOR ITS SECOND ORAL KINASE INHIBITOR, MG516, AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING
4/8/2009	Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
4/7/2009	Glycotex’ Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
4/2/2009	Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
4/1/2009	Alexion Submits NDA in Japan for Soliris(R) (eculizumab) as a Treatment for Patients with PNH
3/31/2009	TorreyPines Therapeutics Reduces Workforce to Three Employees
3/31/2009	MediciNova Reports Fourth Quarter and Full Year 2008 Results
3/30/2009	Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
3/30/2009	METHYLGENE REPORTS FOURTH QUARTER AND FULL YEAR 2008 FINANCIAL RESULTS
3/27/2009	TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
3/23/2009	Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
3/19/2009	Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
3/12/2009	MediciNova Sends Letter to Avigen Board of Directors
2/27/2009	ALEXION JOINS NORD AND EURORDIS IN SUPPORTING THE GOALS OF RARE DISEASE DAY
2/25/2009	Alexion’s Soliris(R) (eculizumab) Receives Marketing Approval in Australia for All Patients with PNH
2/23/2009	Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
2/11/2009	First Multiple Dose Clinical Trial of TorreyPines Therapeutics’ Oral Compound NGX426 Demonstrates Compound is Safe and Well-Tolerated
2/9/2009	MediciNova Reaffirms Proposal to Acquire Avigen, Inc.
1/29/2009	ALEXION’S SOLIRIS(R) (ECULIZUMAB) RECEIVES MARKETING APPROVAL IN CANADA FOR ALL PATIENTS WITH PNH
1/29/2009	NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES CASE REPORTS ON THE INVESTIGATIONAL USE OF SOLIRIS (ECULIZUMAB) IN PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)
1/22/2009	PII AND NEXMED ENTER INTO STRATEGIC COLLABORATION AGREEMENT FOR NEXMED’S NEXACT® DRUG DELIVERY PLATFORM
1/13/2009	Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
1/13/2009	The Immune Tolerance Institute, Sequenom and the University of California, San Francisco to Develop Advanced Diagnostic Test for Severe Combined Immunodeficiency in Newborns
1/12/2009	MediciNova Reports Interim Phase II Data from MN-221 Emergency Department Study
1/12/2009	SOLIRIS(R) RECEIVES ORPHAN DRUG DESIGNATION IN JAPAN
1/5/2009	Micromet Key Events for 2009
1/5/2009	ALEXION PHARMACEUTICALS AND PDL BIOPHARMA RESOLVE PATENT DISPUTE
12/23/2008	MediciNova Proposes to Acquire Avigen, Inc.
12/18/2008	RHEI PHARMACEUTICALS RECEIVES APPROVAL IN CHINA FOR ITS DRS. HANS SCHREUDER SCAR TREATMENT PRODUCT
12/18/2008	Living Cell Technologies Announces Collaboration with Centocor Research & Development, Inc.
12/11/2008	Preclinical Studies Suggest that Living Cell Technologies’ NeurotrophinCell is Effective in Parkinson’s disease
12/9/2008	Micromet Presents Updated Data on the Phase 1 Trial Studying Blinatumomab (MT103/MEDI-538) in Patients with Advanced Non - Hodgkin's Lymphoma
12/9/2008	SOLIRIS® REDUCED MEASURES OF THROMBOSIS AND INFLAMMATION, AND DECREASED INDICATORS OF PULMONARY HYPERTENSION, IN PATIENTS WITH PNH
12/8/2008	Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
12/8/2008	ALEXION REPORTS POSITIVE RESULTS FROM AEGIS REGISTRATION STUDY OF SOLIRIS IN JAPANESE PATIENTS WITH PNH
12/7/2008	FIRST CLINICAL EXPERIENCE WITH SOLIRIS® IN TREATING PATIENTS WITH TWO RARE COMPLEMENT-MEDIATED DISEASES PRESENTED AT ASH ANNUAL MEETING
12/5/2008	RHEI PHARMACEUTICALS ANNOUNCES THE INITIATION OF THE FINAL CLINICAL STUDY FOR APPROVAL OF TIBOZOLE IN CHINA
12/2/2008	TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
12/1/2008	TorreyPines’ NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects
11/25/2008	TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
11/20/2008	RHEI PHARMACEUTICALS ELECTS MRS. ZHENG HONG TO BOARD OF DIRECTORS
11/18/2008	TorreyPines Therapeutics Licenses Posiphen™, Bisnorcymcerine and Phenserine to QR Pharma
11/13/2008	Micromet to Present Interim Data from Two Studies for T Cell Engaging BiTE Antibody Blinatumomab at American Society of Hematolgy Annual Meeting
11/12/2008	TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
11/12/2008	TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
11/10/2008	MediciNova Reports Third Quarter 2008 Results
11/10/2008	Researchers to Present Additional Data on Soliris® (eculizumab) for the Treatment of PNH at the ASH Annual Meeting
11/10/2008	TorreyPines Therapeutics Sells Alzheimer’s Disease Genetics Program to Eisai
11/10/2008	METHYLGENE REPORTS THIRD QUARTER 2008 FINANCIAL RESULTS
11/6/2008	Living Cell Technologies Reports on 12-Month Clinical Effects of DiabeCell® at Annual General Meeting
11/4/2008	Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
10/29/2008	Theratechnologies and EMD Serono Announce Collaboration and Licensing Agreement for Tesamorelin in the United States
10/27/2008	METHYLGENE REACQUIRES RIGHTS TO MGCD0103 FROM CELGENE AND IMPLEMENTS STRATEGIC PLAN TO FOCUS ON DEVELOPMENT OF PROPRIETARY CLINICAL PIPELINE
10/27/2008	METHYLGENE PRESENTS PRECLINICAL DATA FOR MGCD290, A HOS2 FUNGAL INHIBITOR, AT JOINT ICAAC/IDSA ANNUAL MEETING
10/23/2008	Living Cell Technologies Expands Breeding Capability with New Production Facility
10/23/2008	ALEXION REPORTS THIRD QUARTER 2008 RESULTS
10/22/2008	METHYLGENE PRESENTS PRECLINICAL BIOMARKER DATA FOR MGCD265 AT THE 20th EORTC-NCI-AACR-SYMPOSIUM
10/21/2008	Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
10/21/2008	Living Cell Technologies Receives Health Minister’s Approval to Start Leading Edge Live Cell Therapy Clinical Trial in New Zealand for Diabetics
10/20/2008	TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
10/17/2008	Glycotex Finalizes Collaboration Agreement with Advanced Medical Solutions
10/15/2008	METHYLGENE INITIATES PHASE I CLINICAL STUDY WITH MGCD290 FOR FUNGAL INFECTIONS
10/13/2008	CalciMedica Exercises Option to Acquire Additional Intellectual Property from TorreyPines Therapeutics
10/8/2008	CENOMED AND TORREYPINES THERAPEUTICS ENTER INTO LICENSING AGREEMENT
10/3/2008	Micromet Closes $40 Million Private Equity Placement
10/2/2008	METHYLGENE RECEIVES CLINICAL TRIAL APPROVAL FROM HEALTH CANADA FOR ITS PROPRIETARY PRODUCT CANDIDATE MGCD290
10/1/2008	TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting with FDA for Tezampanel
9/30/2008	Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
9/25/2008	ALEXION’S SOLIRIS® RECEIVES 2008 PRIX GALIEN USA AWARD FOR BEST BIOTECHNOLOGY PRODUCT
9/25/2008	TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
9/19/2008	METHYLGENE EXERCISES RIGHT TO CONVERT MGCD0103 COLLABORATION WITH CELGENE TO PRE-DETERMINED ROYALTY AND MILESTONE ARRANGEMENT
9/18/2008	Data from MediciNova’s Two-Year Phase II Clinical Trial of MN-166 in Multiple Sclerosis Presented at the World Congress for Treatment and Research in MS (WCTRIMS)
9/15/2008	Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
9/15/2008	Micromet Presents Data at ESMO 2008 on Anti- EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
9/9/2008	MediciNova Reports Positive Preliminary Results from Phase II Clinical Trial of MN-221 in Moderate to Severe Asthma Patients
9/9/2008	SOLIRIS® REDUCED MEASURES OF THROMBOSIS AND INFLAMMATION, AND DECREASED INDICATORS OF PULMONARY HYPERTENSION, IN PATIENTS WITH PNH
9/2/2008	Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
8/26/2008	TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
8/25/2008	RHEI PHARMACEUTICALS APPOINTS DR. GEERT CAUWENBERGH AS CHIEF EXECUTIVE OFFICER
8/15/2008	METHYLGENE AND CELGENE PROVIDE UPDATE ON SUSPENSION OF NEW ENROLLMENT IN MGCD0103 CLINICAL TRIALS
8/11/2008	MediciNova Reports Second Quarter 2008 Results
8/8/2008	REDPOINT BIO REPORTS SECOND QUARTER AND SIX MONTH 2008 RESULTS
8/7/2008	Micromet, Inc. Reports Second Quarter 2008 Financial Results
8/7/2008	ALEXION SECURES U.S. PATENT FOR ALXN6000, A FIRST-IN-CLASS ANTI-CD200 MONOCLONAL ANTIBODY
8/4/2008	NEXMED CONFIRMS PUBLICATION OF NEW FEMPROX DATA IN THE JOURNAL OF SEXUAL MEDICINE
7/30/2008	METHYLGENE REPORTS SECOND QUARTER 2008 FINANCIAL RESULTS
7/29/2008	ALEXION REPORTS SECOND QUARTER 2008 RESULTS
7/22/2008	NEXMED RECEIVES FDA RESPONSE FOR ED PRODUCT
7/22/2008	METHYLGENE AND CELGENE ANNOUNCE PRECAUTIONARY SUSPENSION OF NEW ENROLLMENTS INTO MGCD0103 CLINICAL TRIALS
7/21/2008	REXAHN PHARMACEUTICALS RECEIVES U.S. PATENT FOR NEW CANCER COMPOUNDS
7/1/2008	NEXMED RECEIVES CASH INFUSION OF $5.75 MILLION
6/30/2008	Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel
6/25/2008	METHYLGENE ANNOUNCES THE INITIATION OF A RANDOMIZED, THREE-ARM PHASE II TRIAL OF MGCD0103 IN COMBINATION WITH VIDAZA IN PATIENTS WITH HIGH-RISK MDS OR AML
6/24/2008	Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
6/23/2008	MediciNova Initiates Phase II Clinical Trial of MN-221 in Moderate to Severe Asthma Patients
6/12/2008	METHYLGENE INITIATES SECOND PHASE I CLINICAL TRIAL WITH MGCD265, A MULTI-TARGETED (C-MET) KINASE INHIBITOR IN PATIENTS WITH SOLID TUMORS
6/12/2008	Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
6/5/2008	Micromet’s BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin’s Lymphoma
6/4/2008	TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
6/3/2008	METHYLGENE REPORTS CLINICAL DATA FROM A PHASE II STUDY EVALUATING MGCD0103 IN RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS AT THE 44TH AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
6/3/2008	NEXMED CONFIRMS PUBLICATION ON ANTI-FUNGAL PRODUCT
6/2/2008	METHYLGENE REPORTS CLINICAL DATA FOR MGCD0103 AT THE 44TH AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
5/16/2008	CLINICAL DATA FOR METHYLGENE’S MGCD0103 TO BE PRESENTED AT THE 2008 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
5/14/2008	NEXMED RECEIVES COMMITMENT FOR $3 MILLION LINE OF CREDIT
5/13/2008	TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
5/12/2008	MediciNova Reports First Quarter 2008 Results
5/12/2008	MethylGene Reports First Quarter 2008 Financial Results
5/9/2008	REDPOINT BIO REPORTS FIRST QUARTER 2008 RESULTS
5/8/2008	NEXMED CONFIRMS DATA PRESENTATIONS ON ANTI-FUNGAL PRODUCT AT TWO PHARMA CONFERENCES
5/1/2008	TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
4/30/2008	ALEXION REPORTS FIRST QUARTER 2008 RESULTS
4/23/2008	Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
4/16/2008	METHYLGENE INITIATES PHASE I CLINICAL TRIAL FOR ITS MULTI-TARGETED(C-MET) KINASE INHIBITOR, MGCD265,IN SOLID TUMOR CANCERS
4/16/2008	METHYLGENE PRESENTS PRECLINICAL DATA FOR ITS MULTI-TARGETED (C-MET) KINASE INHIBITOR, MGCD265, AT AACR ANNUAL MEETING
4/15/2008	METHYLGENE PROVIDES UPDATE ON ITS MGCD0103 HDAC INHIBITOR COLLABORATION WITH CELEGENE
4/14/2008	Micromet Demonstrates that the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted into Highly Potent, T Cell-engaging BiTE Antibodies
4/14/2008	Micromet Presents Safety and Efficacy Data from Primate Studies with Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
4/14/2008	METHYLGENE PRESENTS CLINICAL BIOMARKER DATA FOR MGCD0103 AND PRECLINICAL EFFICACY DATA IN COMBINATION WITH TAXANES AT AACR ANNUAL MEETING
4/14/2008	Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
4/7/2008	MediciNova Reports Clinical Results from Two-Year Phase II Clinical Trial of MN-166 in Multiple Sclerosis
4/7/2008	Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
4/4/2008	METHYLGENE ANNOUNCES ANNUAL MEETING OF SHAREHOLDERS AND CORRECTS PREVIOUSLY DISCLOSED INTERIM DATA FOR TRIAL 005
4/2/2008	MediciNova to Present Additional Clinical Data Demonstrating Potential Neuroprotection Benefits of MN-166 in Multiple Sclerosis at the 18th Meeting of the European Neurological Society
3/31/2008	MediciNova Initiates Phase II Clinical Trial of MN-221 in Status Asthmaticus Patients
3/31/2008	Gamma Secretase Modulators Show Promise in Alzheimer’s Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
3/27/2008	METHYLGENE ANNOUNCES WORLDWIDE RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH OTSUKA PHARMACEUTICAL CO. LTD.
3/26/2008	TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
3/25/2008	Micromet Establishes New Scientific Advisory Board for Its BiTE Antibody Technology with Leading Experts in the Fields of Oncology, Immunotherapy and Drug Development
3/20/2008	Alexion Completes Enrollment in AEGIS Registration Study of Soliris ®(eculizumab) in Patients with PNH in Japan
3/18/2008	TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
3/17/2008	MediciNova Reports Fourth Quarter and Full Year 2007 Results
3/13/2008	Glycotex Completes Enrollment in Phase IIa Study of Lead Product Candidate GLYC-101 for Wound Healing
3/11/2008	REDPOINT BIO CORPORATION RECEIVES U.S. PATENT FOR METHOD OF IDENTIFYING MODULATORS OF KEY ION CHANNEL INVOLVED IN TASTE SIGNALING
3/10/2008	REDPOINT BIO REPORTS FOURTH QUARTER AND YEAR-END 2007 RESULTS
3/10/2008	REDPOINT BIO CORPORATION ANNOUNCES DISCOVERY OF MOLECULAR MECHANISM FOR THYMOL TASTE TRANSDUCTION
3/7/2008	METHYLGENE REPORTS FOURTH QUARTER AND FULL YEAR 2007 FINANCIAL RESULTS
3/5/2008	NEXMED CONFIRMS ACCEPTANCE OF NDS IN CANADA
2/14/2008	TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
2/14/2008	METHYLGENE AND PHARMION ANNOUNCE U.S. ORPHAN DRUG DESIGNATION GRANTED FOR MGCD0103 FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA
2/14/2008	Alexion Reports Fourth Quarter and Full Year 2007 Results
2/14/2008	ALEXION ACQUIRES ALL RIGHTS TO OMRF PATENTS RELATED TO SOLIRIS®
2/11/2008	METHYLGENE AND PHARMION ANNOUNCE ORPHAN DRUG DESIGNATION GRANTED BY THE EUROPEAN MEDICINES AGENCY (EMEA) FOR MGCD0103 FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA
2/8/2008	MEDICINOVA REPORTS CASH, CASH EQUIVALENTS AND SHORT-TERM MARKETABLE SECURITIES AS OF DECEMBER 31, 2007 (UNAUDITED)
2/6/2008	METHYLGENE EXERCISES RIGHT TO OPT-OUT OF HDAC NEURODEGENERATIVE COLLABORATION WITH ENVIVO
2/5/2008	Multiple Dose Clinical Trial of TorreyPines Therapeutics’ Tezampanel Demonstrates Compound is Safe and Well-Tolerated
2/1/2008	MediciNova’s MN-166 Reduces Persistent Black Hole Formation
1/28/2008	METHYLGENE REPORTS MGCD0103 CLINICAL DATA AT THE 2008 GASTROINTESTINAL CANCERS SYMPOSIUM
1/14/2008	Access Licenses MuGard™ to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
1/9/2008	METHYLGENE AND PHARMION START PHASE II COMBINATION CLINICAL TRIAL WITH MGCD0103 AND VIDAZA® IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA OR NON-HODGKIN LYMPHOMA
1/7/2008	Alexion Commences Dosing in AEGIS Registration Study
12/20/2007	Redpoint Bio Names Joseph A. Mollica, Ph.D. Chairman of the Board
12/14/2007	Micromet Announces Changes in Management Team
12/14/2007	Redpoint Bio Signs Research & Technology Development Agreement with The Coca-Cola Company
12/11/2007	Alexion Pharmaceuticals, Inc PNH Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris® Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
12/10/2007	Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics’ Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
12/10/2007	METHYLGENE AND PHARMION PRESENT FAVORABLE CLINICAL DATA FROM COMBINATION MGCD0103/VIDAZA® STUDY IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOGENOUS LEUKEMIA AT THE 49th AMERICAN SOCIETY OF HEMATOLOGY (ASH) MEETING
12/10/2007	Alexion Pharmaceuticals, Inc. LONG-TERM SOLIRIS® THERAPY IMPROVED OR STABILIZED KIDNEY FUNCTION IN PATIENTS WITH PNH
12/10/2007	Micromet and MedImmune Present New Clinical Data for MT103 at the American Society of Hematology Annual Meeting Suggesting Potent Single-Agent Activity in Patients with Relapsed Mantle Cell and Follicular Lymphoma
12/9/2007	METHYLGENE AND PHARMION REPORT FAVORABLE RESULTS FOR PHASE II MGCD0103 SINGLE-AGENT STUDIES IN RELAPSED OR REFRACTORY LYMPHOMAS AT THE 49TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) MEETING
12/7/2007	Alexion Pharmaceuticals to Present Data on Soliris® (Eculizumab)
12/5/2007	Curidium Announces Strategic Partnership with Takeda Research Investment, Inc. -Investment Focus on Major Depressive Disorder-
12/4/2007	SOLIRIS® DEMONSTRATES REDUCTIONS IN HEMOLYSIS AND IMPROVEMENTS IN FATIGUE, OVERALL QUALITY OF LIFE AND ANEMIA IN A BROAD POPULATION OF PNH PATIENTS
11/29/2007	METHYLGENE TO PRESENT CLINICAL DATA FOR MGCD0103 AT THE 49TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY
11/15/2007	CATALYST PHARMACEUTICAL PARTNERS REPORST THIRD QUARTER 2007 FINANCIAL RESULTS
11/15/2007	NEXMED REPORTS THIRD QUARTER 2007 FINANCIAL RESULTS
11/14/2007	PreMD Reports Third Quarter 2007 Results
11/14/2007	TorreyPines Therapeutics Reports Third Quarter 2007 Results
11/9/2007	MediciNova Reports Third Quarter 2007 Results
11/7/2007	METHYLGENE REPORTS THIRD QUARTER 2007 FINANCIAL RESULTS
11/5/2007	SKIN CHOLESTEROL LINKED TO CARDIOVASCULAR DISEASE RISK IN ASYMPTOMATIC INDIVIDUALS
10/25/2007	Alexion Reports Third Quarter 2007 Results
10/25/2007	MediciNova Announces Public Offering of Common Stock
10/24/2007	PreMD Announces Valuable Data on PREVU* LT Life Insurance Product
10/24/2007	METHYLGENE AND PHARMION REPORT PRELIMINARY MGCD0103 CLINICAL DATA AT THE 2007 AACR-NCI-EORTC INTERNATIONAL CONFERENCE
10/23/2007	Micromet Is Presenting Four Posters on BiTE® Antibodies at the International AACR-NCI-EORTC Conference
10/23/2007	Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
10/22/2007	Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
10/22/2007	NEXMED FILES NDS IN CANADA
10/19/2007	MediciNova Reports Phase IIa Clinical Study Results for MN-305, a Treatment for Insomnia
10/18/2007	Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
10/17/2007	Tezampanel, TorreyPines Therapeutics’ Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10/10/2007	METHYLGENE AND PHARMION INITIATE PHASE I COMBINATION CLINICAL TRIAL WITH MGCD0103 AND TAXOTERE® IN PATIENTS WITH SOLID TUMORS
10/9/2007	MediciNova Reports Positive Phase IIa Clinical Study Results for MN-221, a Novel Treatment for Status Asthmaticus
10/5/2007	Redpoint Bio Chief Executive Officer, Dr. Ray Salemme, Featured in CEOcast Interview
10/3/2007	PreMD Inc. Provides Corporate Update
10/2/2007	METHYLGENE PROVIDES CORPORATE UPDATE AT ITS INVESTOR EVENT
10/1/2007	REDPOINT BIO NAMES SCOTT SIEGEL, PH.D. AS VICE PRESIDENT OF CORPORATE DEVELOPMENT
9/27/2007	Positive Clinical Data on MediciNova’s Product Candidate MN-029 Presented at the 14th European Cancer Conference (ECCO 14)
9/25/2007	TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer’s Disease
9/24/2007	METHYLGENE AND PHARMION ANNOUNCE ORPHAN DRUG DESIGNATION GRANTED BY THE EUROPEAN MEDICINES AGENCY (EMEA) FOR MGCD0103 FOR THE TREATMENT OF HODGKIN’S LYMPHOMA
9/24/2007	NEXMED FILES NDA FOR PROPRIETARY ERECTILE DYSFUNCTION TREATMENT
9/19/2007	METHYLGENE PRESENTS PRECLINICAL DATA FOR ITS CLINICAL CANDIDATE MGCD290, AN ANTIFUNGAL HISTONE DEACETYLASE INHIBITOR
9/19/2007	ALEXANDRIA REAL ESTATE EQUITIES, INC. ANNOUNCES FOLLOW-ON PUBLIC OFFERING OF 2,000,000 SHARES OF COMMON STOCK
9/19/2007	ALEXANDRIA REAL ESTATE EQUITIES, INC. DECLARES QUARTERLY CASH DIVIDEND
9/12/2007	REDPOINT BIO APPOINTS NEW BOARD MEMBERS
9/12/2007	Micromet Appoints Mark Reisenauer as Senior Vice President and Chief Commercial Officer
9/11/2007	MediciNova Announces Rule 10b5-1 Stock Purchase Plan
9/10/2007	TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, A Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9/6/2007	PreMD Provides Update on 510(k) Application for PREVU* POC
9/5/2007	Columbia Laboratories and DesignRxclusive Increase Access to CRINONE 8% Progesterone Gel for Uninsured Patients
9/5/2007	AKELA PHARMA INC. ANNOUNCES POSITIVE RESULTS FOR THE EXTENSION PART OF ITS PHASE IIB FENTANYL TAIFUN® TRIAL
9/5/2007	Redpoint Bio Chief Executive Officer, Dr. Ray Salemme, To Be Interviewed Live On Market News First
9/4/2007	NATIONSHEALTH ACQUIRES DIABETES CARE & EDUCATION, INC.
8/27/2007	AKELA PHARMA INC. ENROLLS FIRST PATIENT IN ITS PHASE IIB CGRP TRIAL
8/27/2007	TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
8/23/2007	New Breast Cancer Clinical Data Accepted for Presentation at San Antonio Breast Cancer Symposium
8/21/2007	METHYLGENE AND PHARMION ANNOUNCE U.S. ORPHAN DRUG DESIGNATION GRANTED FOR MGCD0103 FOR THE TREATMENT OF HODGKIN’S LYMPHOMA
8/20/2007	NationsHealth Warrants to Expire on August 24, 2007
8/20/2007	PNH Patients Treated with Soliris™ Experienced Dramatic Reduction in Blood Clots During Clinical Trials
8/20/2007	METHYLGENE AND PHARMION ANNOUNCE COLLABORATION TO DEVELOP SIRTUIN INHIBITORS AS ANTI-CANCER AGENTS
8/17/2007	MediciNova Reports Phase Ib Clinical Study Results for MN-221, a Novel Treatment for Preterm Labor
8/15/2007	Redpoint Bio Announces Interview with WallSt.net
8/14/2007	REDPOINT BIO REPORTS SECOND QUARTER 2007 FINANCIAL RESULTS
8/14/2007	NEXMED REPORTS SECOND QUARTER 2007 FINANCIAL RESULTS
8/14/2007	PreMD Reports Second Quarter 2007 Results
8/14/2007	AKELA PHARMA INC REPORTS RESULTS FOR SECOND QUARTER OF FISCAL 2007
8/14/2007	PASA Abstract to be presented at American Heart Association Conference
8/13/2007	TorreyPines Therapeutics Reports Second Quarter 2007 Results
8/10/2007	MediciNova Reports Second Quarter 2007 Results
8/9/2007	Data from MediciNova’s Phase II Trial of MN-166 Selected for Presentation at the 23rd Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) and the 12th Conference of Rehabilitation in Multiple Sclerosis (RIMS)
8/9/2007	MediciNova to Present Clinical Data on MN-029 at the 14th European Cancer Conference (ECCO 14)
8/9/2007	NATIONSHEALTH ANNOUNCES 2007 SECOND QUARTER AND YEAR TO DATE FINANCIAL RESULTS
8/8/2007	Micromet, Inc. Reports Second Quarter 2007 Financial Results
8/7/2007	METHYLGENE REPORTS SECOND QUARTER 2007 RESULTS
8/6/2007	TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8/1/2007	METHYLGENE REGAINS EXCLUSIVE RIGHTS TO BETA-LACTAMASE INHIBITOR PROGRAM FROM MERCK
7/30/2007	NATIONSHEALTH RECEIVES ACCREDITATION
7/25/2007	Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2007 Financial Results
7/25/2007	Alexion Reports Second Quarter 2007 Results
7/23/2007	AKELA PHARMA INC. COMPLETES PATIENT ENROLLMENT IN ITS FENTANYL TAIFUN® PHASE IIB TRIAL
7/20/2007	REDPOINT BIO CORPORATION ANNOUNCES EFFECTIVENESS OF REGISTRATION STATEMENT
7/19/2007	Micromet Promotes Carsten Reinhardt to Chief Medical Officer
7/16/2007	PreMD Signs Marketing and Distribution Agreement with AstraZeneca
7/16/2007	Alexandria Real Estate Equities, Inc. Celebrates 10th Anniversary on NYSE
7/12/2007	METHYLGENE INITIATES SINGLE-AGENT PHASE II CLINICAL TRIAL WITH ITS HDAC INHIBITOR, MGCD0103, IN PATIENTS WITH REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
7/11/2007	TRACON Pharmaceuticals and Micromet Announce the Initiation of Phase 1 Clinical Trial with TRC093 (D93), a Humanized Antibody for Cancer Treatment
7/9/2007	NEXMED ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN TWO PIVOTAL PHASE 3 STUDIES FOR ANTI-FUNGAL PRODUCT
7/9/2007	NEXMED ANNOUNCES ITS INCLUSION IN THE RUSSELL MICROCAP® INDEX
6/29/2007	NEW TICKER SYMBOL FOR REDPOINT BIO CORPORATION
6/26/2007	MaRS Selects Alexandria Real Estate Equities to Expand the MaRS Centre in the Discovery District of Toronto
6/26/2007	MediciNova Announces New Strategic Initiative
6/26/2007	Publication Confirms that EpCAM, the Target for Two of Micromet’s Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
6/22/2007	ALEXION’S SOLIRIS™ GRANTED MARKETING APPROVAL IN EUROPE FOR TREATMENT OF ALL PATIENTS WITH PNH
6/20/2007	Micromet Announces Definitive Agreement for $25.0 Million Private Placement
6/20/2007	NEXMED APPOINTS VIVIAN LIU AS CHIEF EXECUTIVE OFFICER
6/20/2007	SCOTT HORVITZ OF REDPOINT BIO NAMED CFO OF THE YEAR BY NEW JERSEY TECHNOLOGY COUNCIL
6/19/2007	American Stock Exchange Accepts PreMD’s Continued Listing Plan
6/18/2007	ROBCOR PROPERTIES, INC. MERGES WITH AND INTO ITS WHOLLY-OWNED SUBSIDIARY REDPOINT BIO CORPORATION
6/18/2007	ALEXANDRIA REAL ESTATE EQUITIES, INC. DECLARES QUARTERLY CASH DIVIDEND
6/11/2007	STUDIES SHOW EFFICACY AND SAFETY OF ALEXION’S SOLIRIS™ IN BROAD POPULATION OF PNH PATIENTS
6/6/2007	PreMD Submits 510(k) to the FDA for Expanded Regulatory Claim for PREVU* POC
6/4/2007	SOLIRIS(TM) EFFECTIVE IN PNH PATIENTS WITH HISTORY OF APLASTIC ANEMIA AND MYELODYSPLASTIC SYNDROMES
6/4/2007	Final Data from a Phase 2 Trial Presented at ASCO Specifies Dose-dependent Activity of Adecatumumab (MT201)
6/4/2007	METHYLGENE REPORTS PHASE I DATA ON MGCD0103 IN ADVANCED LEUKEMIAS AND MYELODYSPLASTIC SYNDROME (TRIAL 004) AT ASCO
6/2/2007	METHYLGENE AND PHARMION REPORT PRELIMINARY DATA FOR MGCD0103 AT THE 43rd AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
5/31/2007	ADVANCED BIOHEALING CLOSES SECOND TRANCHE OF SERIES C FINANCING
5/29/2007	PreMD Inc. Receives Notice of Allowance for a United States Patent on PREVU* LT
5/24/2007	Micromet and Nycomed Enter Into Exclusive Worldwide Collaboration to Develop and Commercialize anti-GM-CSF Antibodies for the Treatment of Inflammatory and Autoimmune Diseases
5/24/2007	METHYLGENE PRESENTS PRECLINICAL DATA FOR ITS CLINICAL CANDIDATE MGCD290 – AN ANTIFUNGAL HISTONE DEACETYLASE INHIBITOR
5/21/2007	REDPOINT BIO RELOCATES CORPORATE HEADQUARTERS AND RESEARCH FACILITY
5/17/2007	METHYLGENE SELECTS HISTONE DEACETYLASE ANTIFUNGAL CLINICAL CANDIDATE
5/14/2007	TorreyPines Therapeutics Reports First Quarter 2007 Results
5/12/2007	Curidium Announces Strategic Partnership with Takeda Research Investment, Inc. -Investment Focus on Major Depressive Disorder-
5/11/2007	PreMD Reports First Quarter 2007 Results
5/10/2007	NEXMED REPORTS FIRST QUARTER 2007 FINANCIAL RESULTS
5/10/2007	METHYLGENE REPORTS FIRST QUARTER 2007 RESULTS
5/9/2007	Micromet, Inc. reports first quarter 2007 financial results
5/7/2007	TorreyPines Therapeutics Transfers Intellectual Property and Compounds for Treating Autoimmune Diseases to CalciMedica
5/3/2007	ALEXANDRIA REAL ESTATE EQUITIES, INC. REPORTS FIRST QUARTER 2007 RESULTS
5/1/2007	Alexion Pharmaceuticals Reports First Quarter 2007 Results
4/27/2007	CHMP ADOPTS POSITIVE OPINION FOR ALEXION’S SOLIRIS™ IN EUROPE
4/26/2007	Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
4/25/2007	RIB-X PHARMACEUTICALS AND THE MEDICAL RESEARCH COUNCIL ANNOUNCE KEY COLLABORATION
4/19/2007	MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE® Molecule
4/18/2007	Micromet and MedImmune Present Data from Preclinical Study of New BiTE® Molecule Targeting CEA
4/17/2007	METHYLGENE PRESENTS CLINCAL BIOMARKER DATA FOR MGCD0103 AT AACR ANNUAL MEETING
4/16/2007	Alexandria Real Estate Equities, Inc. Announces Filing of Resale Shelf Registration Statement
4/12/2007	NATIONSHEALTH ANNOUNCES $7.0 MILLION TERM LOAN FACILITY
4/9/2007	REDPOINT BIO CORPORATION COMPLETES FINAL CLOSING OF $33 MILLION PRIVATE PLACEMENT
4/2/2007	Data on PreMD’s New PREVU* Tape POC Format to be Presented at American Association for Clinical Chemistry Meeting
3/29/2007	TorreyPines Therapeutics Reports 2006 Results
3/29/2007	PreMD Reports Fiscal 2006 Results and Provides Outlook for 2007
3/27/2007	Scientific Founder of TorreyPines Therapeutics Honored by Alzheimer’s Association
3/27/2007	Redpoint Bio Signs Multi-Year Research & Development Collaboration and Licensing Agreement with Givaudan
3/27/2007	NEXMED REPORTS 2006 YEAR END FINANCIAL RESULTS
3/21/2007	PreMD Announces Private Placement
3/16/2007	Micromet and TRACON Pharmaceuticals Sign Exclusive Worldwide License Agreement to Develop and Commercialize D93, a Humanized Antibody for Cancer Treatment
3/16/2007	FDA APPROVES ALEXION’S SOLIRIS™ FOR ALL PATIENTS WITH PNH
3/16/2007	Micromet, Inc. reports fourth quarter and full year 2006 financial results
3/15/2007	NATIONSHEALTH ANNOUNCES 2006 FOURTH QUARTER AND ANNUAL FINANCIAL RESULTS
3/13/2007	PreMD Provides Update on 510(k) Application for PREVU* LT
3/12/2007	REDPOINT BIO CORPORATION AND ROBCOR PROPERTIES, INC. COMPLETE REVERSE MERGER AND RAISE APPROXIMATELY $20 MILLION IN PRIVATE PLACEMENT TRANSACTION
3/12/2007	TorreyPines Therapeutics Initiates Phase I Multiple Dose Clinical Trial of NGX267, A Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
3/8/2007	METHYLGENE REPORTS YEAR-END 2006 FINANCIAL RESULTS
3/7/2007	Publication Confirms that EpCAM, the Target for Two of Micromet’s Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
3/7/2007	Alexandria Real Estate Equities, Inc. Elects John L. Atkins, III to the Company’s Board of Directors
2/27/2007	Advanced BioHealing Raises $25.5 Million in Series C Financing
2/26/2007	TorreyPines Therapeutics Initiates Second Phase I Clinical Trial of NGX426, a Potential Novel Oral Treatment for Chronic Pain Conditions
2/22/2007	TorreyPines Therapeutics and Eisai Co., Ltd. Extend Alzheimer’s Disease Collaboration Agreement
2/22/2007	Micromet, Inc. to Participate in Pacific Growth Equities One on One Sessions 2007: Oncology Conference
2/15/2007	Advanced BioHealing Launches Dermagraft®
2/12/2007	Morphotek Obtains Exclusive License from Micromet for Antibody to Treat Melanoma and other Cancers
2/8/2007	Advanced BioHealing Enrolls First Patient in Celaderm™ Pilot Venous Leg Ulcer Clinical Trial
1/29/2007	Micromet Reports on First International Symposium on EpCAM Biology and Clinical Application
1/8/2007	PreMD Retains License Agreement for Cancer Patents
12/19/2006	Theratechnologies Reports Positive Phase 3 Results for TH9507 in HIV associated Lipodystrophy
12/15/2006	METHYLGENE TO INCREASE INVESTMENT IN HDAC AND KINASE (c-MET) SMALL MOLECULE PROGRAMS
12/11/2006	POSITIVE DATA REPORTED AT ASH ANNUAL MEETING FOR METHYLGENE’S MGCD0103, AN ORAL, ISOTYPE-SELECTIVE HDAC INHIBITOR
12/7/2006	METHYLGENE INITIATES PHASE II CLINICAL TRIAL WITH ITS PROPRIETARY HDAC INHIBITOR, MGCD0103, IN HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOGENOUS LEUKEMIA (AML)
12/7/2006	METHYLGENE SELECTS MULTI-TARGETED KINASE (C-MET) CLINICAL CANDIDATE FOR ONCOLOGY
12/6/2006	PreMD Announces Ontario Court Reserves Decision
12/5/2006	ARBIOS SYSTEMS CHIEF SCIENTIFIC OFFICER PRESENTS AT THE ACUTE LIVER FAILURE WORKSHOP, SPONSORED BY THE NIH
12/4/2006	METHYLGENE ANNOUNCES TWO POSTER PRESENTATIONS HIGHLIGHTING ITS LEAD HDAC INHIBITOR, MGCD0103, AT THE 48TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY
11/21/2006	PreMD Announces Order Issued in Maryland Court - Antisuit Motion Denied to Shamsuddin and Med-11 AG -
11/21/2006	ALEXION PHARMACEUTICALS ANNOUNCES CLOSING OF PUBLIC OFFERING OF STOCK
11/16/2006	METHYLGENE AND ENVIVO PHARMACEUTICALS FORM COLLABORATION WITH CHDI, INC., IN SUPPORT OF HDAC PROGRAM FOR HUNTINGTON’S DISEASE
11/15/2006	ARBIOS SYSTEMS ANNOUNCES ADDITION OF SENIOR PERSONNEL
11/15/2006	ALEXION PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
11/14/2006	ALEXION PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
11/14/2006	FDA Grants Priority Review for Soliris™ (eculizumab) BLA for Treatment of Paroxysmal Nocturnal Hemoglobinuria
11/9/2006	DATA FROM METHYLGENE’S ONCOLOGY PROGRAMS TO BE REPORTED AT THE 18th EORTC-NCI-AACR CANCER SYMPOSIUM IN PRAGUE
11/9/2006	Alexion Pharmaceuticals’ Soliris™ (Eculizumab) Data to be Presented at 2006 American Society of Hematology (ASH) Annual Meeting
11/9/2006	Micromet, Inc. reports third quarter 2006 financial results
11/9/2006	PreMD Reports Third Quarter Results
11/9/2006	COLUMBIA LABORATORIES REPORTS THIRD QUARTER 2006 FINANCIAL RESULTS
11/7/2006	Columbia Laboratories Advances Clinical Development of Lidocaine Candidate
11/6/2006	PreMD Submits 510(k) Application to FDA for PREVU* LT
11/6/2006	Antisuit Injunction Materials Served
11/2/2006	TorreyPines Therapeutics Completes Phase I Trial for NGX426, a Novel Oral Treatment for Pain
11/1/2006	METHYLGENE ANNOUNCES THIRD QUARTER 2006 RESULTS
11/1/2006	PreMD Announces Order Made by Judge in Ontario Court
10/31/2006	METHYLGENE TO PRESENT AT THE RODMAN & RENSHAW AND CIBC HEALTHCARE CONFERENCES
10/26/2006	METHYLGENE INITIATES PHASE I/II COMBINATION CLINICAL TRIAL WITH ITS PROPRIETARY HDAC INHIBITOR, MGCD0103, AND GEMZAR® IN PATIENTS WITH PANCREATIC CANCER
10/25/2006	Theratechnologies: last patient treated in pivotal TH9507 trial
10/25/2006	PreMD Commences Action in Ontario Court
10/25/2006	Micromet Presents New Anti-IL-2 Antibody with Unique Mode of Action
10/24/2006	ALANTOS PHARMACEUTICALS AND SERVIER FORM COLLABORATION
10/16/2006	TorreyPines Therapeutics Initiates Phase IIb Clinical Trial in Acute Migraine for Lead Compound Tezampanel
10/12/2006	Micromet, Inc. Expands Management and Appoints Christopher P. Schnittker as Senior Vice President and Chief Financial Officer
10/4/2006	TorreyPines Therapeutics Initiates Phase I Clinical Trial of NGX426, a Novel Oral Therapy for Migraine and Neuropathic Pain
10/4/2006	Syngenta’s corn rootworm biotech trait approved in the USA
10/3/2006	Syngenta obtains first regulatory approvals for new fungicide Revus™
10/2/2006	Final Data from Two Phase II Trials Indicate Activity of Adecatumumab (MT201) in Breast and Prostate Cancer
10/2/2006	A.P. PHARMA LICENSES APF530 TO RHEI PHARMACEUTICALS FOR DEVELOPMENT IN GREATER CHINA
9/29/2006	ARBIOS GRANTED FDA ALLOWANCE TO EXPAND SEPET™ CLINICAL TRIAL ELIGIBILITY
9/29/2006	METHYLGENE REPORTS PRECLINICAL RESULTS OF ITS ANTIFUNGAL COMPOUND MG3290 IN COMBINATION WITH AZOLES
9/27/2006	PreMD’s PREVU* LT Cleared For Sale in Canada
9/26/2006	License, Development and Supply Agreements to Terminate
9/25/2006	MorphoSys and U.S. Army Enter into Biodefense Cooperation
9/20/2006	PreMD Receives FDA Clearance for New Handheld PREVU* Reader
9/20/2006	Alexion Pharmaceuticals Submits Biologics License Application for Soliris™ (eculizumab)
9/20/2006	Soliris™ (eculizumab) Demonstrates Significant Improvement in PNH Study –Phase III TRIUMPH Study Published in New England Journal of Medicine–
9/18/2006	PreMD’s PREVU* LT Cleared For Sale in Europe
9/15/2006	METHYLGENE INITIATES PHASE II CLINICAL TRIAL WITH PROPRIETARY HDAC INHIBITOR, MGCD0103, IN B-CELL LYMPHOMA
8/22/2006	METHYLGENE’S HDAC INHIBITOR, MGCD0103, ENTERS PHASE II CLINICAL TRIAL IN PATIENTS WITH REFRACTORY OR RELAPSED HODGKIN’S LYMPHOMA
8/21/2006	MedImmune Files Investigational New Drug Application for MT103
8/16/2006	ALANTOS PHARMACEUTICALS INITIATES PHASE 1 CLINICAL STUDIES WITH LEAD COMPOUND FOR TYPE II DIABETES
8/9/2006	NEXMED DEVELOPS ROOM TEMPERATURE FORMULATION OF ALPROX-TD FOR ERECTILE DYSFUNCTION
8/9/2006	Micromet, Inc. reports second quarter 2006 financial results
8/9/2006	NEXMED REPORTS SECOND QUARTER 2006 FINANCIAL RESULTS
8/9/2006	PreMD Reports Second Quarter Results
8/9/2006	METHYLGENE ANNOUNCES SECOND QUARTER 2006 RESULTS
8/8/2006	Alexion Pharmaceuticals Reports Second Quarter 2006 Results
8/8/2006	PreMD’s New Handheld PREVU* Reader Cleared by Health Canada
8/3/2006	METHYLGENE TO PRESENT AT THE 2006 MEDICINAL CHEMISTRY GORDON CONFERENCE
8/1/2006	PreMD Receives CE Mark for New Handheld PREVU* Reader
7/27/2006	PreMD’s New LungAlert™ Test Format Presented at the 2006 AACC Annual Meeting
7/26/2006	PreMD Submits Special 510(k) Application to FDA for New Handheld PREVU* Reader
7/24/2006	TorreyPines Therapeutics Completes Second Phase I Study for NGX267, a Selective M1 Agonist for the Treatment of Alzheimer’s Disease
7/21/2006	MedImmune and Micromet Report on Novel Anti-cancer BiTE®
7/13/2006	Alexion Pharmaceuticals Purchases Biopharmaceutical Manufacturing Site in Rhode Island
7/12/2006	PreMD Reports Positive Interim Results from PREPARE Study